Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Everolimus Offers No Survival Benefit in Non–Clear Cell RCC
TOPLINE: Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma (RCC) and is associated with higher rates of severe adverse events compared with placebo. METHODOLOGY: Non–clear cell…
English